Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
112 Cards in this Set
- Front
- Back
synergistic effect |
a drug interaction that results from combined drug effects that are greater than those that could have been achieved if the drug were gived alone
|
|
substrate
|
a substance on which an eczyme acts
|
|
steady state
|
the physiologic state in which the amount of drug removed via elimination is equal to the amount of drug absorbed with each dose
|
|
side effect
|
any undesirable effect of a medication that is expected or anticipated to occur in a predictable percentage of pt who recieve a given med
|
|
receptor
|
a molecular structure within or on the outer surface of cells receptors are characterized by the binding of specific substances
|
|
prodrug
|
an inactive drug dosage form that is converted to an active metabolite by various biochemical chemical reactions once inside the body
|
|
pharmacogenetics
|
the study of genetic factors and their influence on drug response
|
|
parent drug
|
the chemical form of a drug that is administered to the body before it is metabolized by the bodys biochemical reactions into its active or inactive metabolites
|
|
3 primary protiens that bind to and carry drugs
|
albumin, alpha-acid glycoprotein, corticosteroid-binding globulin
|
|
3 routes of administration
|
enteral, patenteral, topical
|
|
bioequivalent
|
two meds have the same bioavailability
|
|
pharmacodynamic phase
|
drug receptor interaction
|
|
pharmacokinetics
|
absorption, distribution,metabolism,excretion
|
|
pharmaceutical phase
|
disintegration of dosage form dissolution of drug
|
|
pharmaceutics,pharmacokinectics,pharmacodynamics describe what
|
the relationship between the dose of a drug give to a pt and the effectiveness of the drug in treating the pt's disease
|
|
metabolites
|
a chemical form of a drug that is the product of one or more biochemical metabolic reactions involving the parent drug.
|
|
incompatibility
|
reaction that occurs when two parenteral drugs or solutions are mixed together resulting in chemical deterioration of at least one of the drugs
|
|
idiosyncratic reaction
|
an abnormal and unexpected susceptibility to a medication other that an allergic reaction that is peculiar to an individual pt
|
|
latrogenic hazard
|
any potential or actual pt harm that is caused by errant actions of health care staff members
|
|
cytochrome p-450
|
general term for a wide variety of tissue enzymes that play a significant role in drug metabolism
|
|
contraindication
|
any condition including any current or recent drug therapy especially related to disease states or other pt characteristics that renders a particular form of treatment improper or undesirable
|
|
duration of action
|
the length of time that a drug concentration in the blood or tissues is suffecient to elicit a therapeutic response
|
|
toxicology
|
the study of poisions and unwanted responses to therapeutic agents
|
|
latrogenic response
|
unintentional adverse effects that are treatment induced
|
|
therapeutic index
|
the ratio between a drug's therapeutic benefit and it's toxic effects
|
|
pharmacotherapeutics types of therapy
|
acute,maintenance,supplemental,palliative,supportive,prophylactic,empiric
|
|
3 mechanisms of action in pharmacodynamics
|
receptor interactions,enzyme interactions,nonspecific interactions
|
|
once a drug is at the site of action what does it do
|
it can modify the rate at which the cells or tissues function
|
|
drug effect
|
the physiologic reaction of the body to the drug
|
|
drug action
|
the cellular processes involved in the drug and cell interaction
|
|
duration
|
the time a drug concentration is sufficient to elicit a therapeutic response
|
|
peak
|
time it takes for a drug to reach its maximum therapeutic response
|
|
onset
|
time it takes for the drug to elicit a therapeutic response
|
|
half life
|
the time it takes for one half of the original amount of a drug in the body to be removed
|
|
stimulating drug metabolism causes
|
diminished pharmocologic effects
|
|
delayed drug metabolism results in
|
accumulation of drugs prolonged action of the drug
|
|
factors that increase metabolism
|
fastacetylator,barbiturate,
rifampin therapy |
|
metabolism is the biologic transformation of a drug into
|
an inactive metabolite,a more soluable compound, a more potent metabolite
|
|
drug metabolism or biotransformation
|
the biologic transformation of a drug into an inactive metabolite , a more soluable compound or a more potent metabolite
|
|
areas of rapid distribution
|
heart,liver,kidneys,brain
|
|
drug distribution
|
the transport of a drug in the body by the bloodstream to its site of action
|
|
topical routes
|
skin,eyes,ears,nose,lungs,vagina
|
|
parenteral routes
|
intravenous,im,subq,id,intrathecal,intraarticular
|
|
non first pass routes
|
aural,buccal,inhalation,intraarterial,im,intranasal,intraocular,intravaginal,intravenous,subq,sublingual,transdermal
|
|
first pass routes
|
hepatic artery,oral,portal vein,rectal
|
|
first pass effect
|
the metabolism of a drug and its passage from the live into the circulation
|
|
a drugs route of administration effects
|
the rate and extent of absorption of that drug
|
|
oral meds rely on - to break down drug for absorption
|
gastric, intestinal enzymes and ph
|
|
pharmacokinetics: absorption
|
the rate at which a drug leaves its site of administration and the extent to which absorption occurs
|
|
pharmacognosy
|
study of natural drug sources
|
|
pharmacotherapeutics
|
the use of drugs and the clinical indications for drugs to prevent and treat diseases
|
|
pharmacodynamics
|
the study of what the drug does to the body
|
|
4 phases of pharmacokinetics
|
absorption,distribution,metabolism,excretion
|
|
pharmacokinetics
|
the study of what the body does to drugs
|
|
pharmaceutics
|
the study of how various drug forms influence pharmacokinetic and pharmacodynamic activities
|
|
drug
|
any chemical that affects the physiologic processes of a living organism
|
|
nursing process
|
assessment dx planning implmentation, evaluation
|
|
trade name
|
drug has a registered trademark
|
|
chemical name
|
describes a drug's chemical composition and molecular structure
|
|
generic name
|
name given to a drug also called nonproprietary name
|
|
dissolution
|
process of how solid forms of drugs disintegrate in the gastrointestinal tract, become soluable and get absorbed into circulation
|
|
bioavailability
|
term used to quantify the extent of drug absorption
|
|
antagonist
|
drug binds to and inhibits the activity of one or more biochemical receptor types in the body resulting in inhibitory or antagonistic drug effects
|
|
antagonistic effect
|
a drug interaction that results in combined drug effects that are less that those that could be achieved if either drug were given alone
|
|
agonist
|
drug that binds to and stumulates the activity of one or more biochemical receptor types in the body resulting in stimulatory or agonstic drug effects
|
|
ADE adverse drug event
|
an injury caused by a medication or failure to administer an intended medication
|
|
additive effect
|
result of a drug interaction that occurs when two drugs with similar actions are given together. also called synergistic effect
|
|
5 rights
|
rigth drug, right dose, right time, right route, right pt
|
|
drug order must contain 6 elements
|
pt name, date order written, name of med, dosage, route of delivery, signature of prescriber
|
|
drug polymorphism
|
variation in response to drug because of a pt's age, gender, size and body compostion
|
|
pc
|
after meals
|
|
ac
|
before meals
|
|
BRP
|
bathroom privilages
|
|
excretion of pediatric pt |
kidneys immature affects glomerular filtration rate and tubular secretion decreased perfusion rate of the kidneys.
|
|
metabolism in ped pt.
|
liver immature
|
|
category x
|
fetal abnormalities reported and positive evidence of fetal risk in humans is available from studies should not be used in pregnant women
|
|
category D
|
possible fetal risk in humans reported consider benefits VS risk may in some cases warrant use
|
|
category C
|
adverse effects reported on animal fetuses. info on humans not avaioable.
|
|
category B
|
studies indicate no risk to animal fetus info on humans unavailable
|
|
category A
|
studies indicate no risk to human fetus
|
|
which stage of pregnancy is the greatest danger for drug induced development defects
|
first trimester
|
|
synergistic effect
|
a drug interaction that results from combined drug effects that could have been achieved if the drugs where given alone
|
|
substrate
|
a substance on which an enzyme acts
|
|
durham-humphrey amendment
|
the act of 1951 differentiated between prescription and otc drugs also which drugs could be refilled without a prescription
|
|
federal food and drug act
|
first fed law that attempted to protect the public from danger 1906
|
|
federal food, drug and cosmetic act
|
1938 act required drug manufactures to apply for an IND exemption for a safety review before marketing new drugs
|
|
harrison narcotic act
|
1914 established the legal term narcotic
|
|
sherley amendment
|
1912 prohibited labeling of med with false therapeutic claims intending to defraud the purchaser
|
|
kefauver-harris amendment
|
1962 required drug to be proved safe and effective before being approved
|
|
controlled substance act
|
1970 promotes research on drug abuse prevention education treatment rehabilitation and enhancement of law enforcement
|
|
orphaned drug act
|
1983 aid in the development of drugs for treatment of rare diseases
|
|
autonomy
|
self determination and ability to act on one's own
|
|
investigational new drug
|
drug not approved by the FDA but available for use in experiments to determine its safety and effects
|
|
2 types of ADR's - Adverse Drug Reaction |
allergic and idiosyncratic (unintended) |
|
nonmaleficence
|
the duty to do no harm to a client
|
|
justice
|
being fair or equal in one's actions
|
|
beneficence
|
the doing or active promotion of good implications include how the patient is best served
|
|
opioids produce
|
analgesia, drowsiness, euphoria, tranquility, other mood alterations
|
|
commonly abused substances
|
opioids stimulants depressants alcohol nicotine
|
|
drug used for withdrawl of opioid
|
clondine, methadone
|
|
amphetamines, cocaine, methylphenidate are what
|
stimulants
|
|
effects that lead to abuse of stimulants
|
elevation of mood, reduction of fatigue, sense of incresed alertness, invigoration alertness
|
|
benzodiazepine and barbiturates are
|
depressants
|
|
flumazenil ( romazicon)
|
may be used to reverse the acute sedative effects of benzodiazepines
|
|
3 ethanol withdrawl treatment drugs |
diazepam ( valium ), lopazepam ( ativan ), disulfiram ( antabuse ). |
|
legend drugs
|
meds not legally available without a prescription
|
|
opioid analgesic
|
synthetic pain-relieving substance that originated from the opium plant.
|
|
narcotic
|
any agent that produces insensibility or stupor
|
|
amphetamines
|
drugs that stimulate the CNS
|
|
how opioids work
|
they block receptors in the cns blocking pain
|
|
stimulants work by
|
releasing biogenic amines form their storage sites in the nerve terminals main one is norepinephrine
|
|
how do benzodiazepines and barbiturates work
|
they increase the action of gamma-aminobutyric acid
|